No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

NCT05556746Phase 2Active Not Recruiting94 enrolled

Uniform Multidrug Therapy Regimen for Leprosy Patients

NCT00669643Phase 4Completed859 enrolled

Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy

NCT01290744Phase 4Completed100 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Effectiveness and safety of multidrug therapy containing clofazimine for paucibacillary leprosy and clarithromycin for rifampicin-resistant leprosy: a systematic review and meta-analysis.

Montezuma Thais, Vernal Sebastian, Andrade Elaine Nascimento et al. · Front Med (Lausanne) · 2023

PMID: 37234244Meta-AnalysisFull text (PMC)

Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study.

Hajikhani Bahareh, Nasiri Mohammad Javad, Hosseini Sareh Sadat et al. · J Glob Antimicrob Resist · 2021

PMID: 34153525Meta-Analysis

Role of Clofazimine in Treatment ofComplex.

Nasiri Mohammad Javad, Calcagno Tess, Hosseini Sareh Sadat et al. · Front Med (Lausanne) · 2021

PMID: 33968952Meta-AnalysisFull text (PMC)

Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Kadura Suha, King Nicholas, Nakhoul Maria et al. · J Antimicrob Chemother · 2020

PMID: 32361756Meta-AnalysisFull text (PMC)

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Hwang Thomas J, Dotsenko Svetlana, Jafarov Azizkhon et al. · BMJ Open · 2014

PMID: 24384902Meta-AnalysisFull text (PMC)

Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.

Dey Teesta, Brigden Grania, Cox Helen et al. · J Antimicrob Chemother · 2013

PMID: 23054996Meta-Analysis

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Gopal M, Padayatchi N, Metcalfe J Z et al. · Int J Tuberc Lung Dis · 2013

PMID: 23541151Meta-AnalysisFull text (PMC)

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

Metcalfe John Z, Weir Isabelle R, Scarsi Kimberly K et al. · Lancet Infect Dis · 2026

PMID: 40915311RCT

Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial.

Shafiq Nusrat, Kumar Ashok, Vohra Vikram et al. · J Antimicrob Chemother · 2025

PMID: 40478219RCT

Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.

Zweijpfenning Sanne M H, Aarnoutse Rob, Boeree Martin J et al. · Chest · 2024

PMID: 38040054RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Clofazimine (substance)
SNOMED CT: 387410004
UMLS CUI: C0008996
RxNorm CUI: 2592

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.